<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20660" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biochemistry, Dopamine Receptors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhatia</surname>
            <given-names>Anmol</given-names>
          </name>
          <aff>A.T.Still University-School of Osteopathic Med</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lenchner</surname>
            <given-names>Jennifer R.</given-names>
          </name>
          <aff>LECOM - Seton Hill</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anmol Bhatia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jennifer Lenchner declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20660.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cell-to-cell communication is critical&#x000a0;for the survival of&#x000a0;an organism. Cells can communicate through a process called the signal transduction pathway. When sending a signal, different molecules, such as hormones, can bind to a receptor on or inside the cell membrane, leading to chemical reactions in the cell, ultimately reaching the target. Cells use a second messenger to transmit these messages.&#x000a0;</p>
        <p>This article will be discussing the different types of receptors, focusing specifically on dopamine receptors, the different types of dopamine receptors, and what function each receptor has. The article will also go into different illnesses and medications that target these receptors. The dopamine receptors affect many various functions, ranging from hypertension and hormonal regulation to voluntary movement and reward.<xref ref-type="bibr" rid="article-20660.r1">[1]</xref></p>
      </sec>
      <sec id="article-20660.s2" sec-type="Fundamentals">
        <title>Fundamentals</title>
        <p>There are many different types of signaling receptors in the human body, with the majority being the G-protein coupled receptors (GPCRs). GPCRs have an intracellular C-terminus and an extracellular N-terminus. GPCRs are also known as the seven-pass transmembrane proteins; this is because the receptor consists of seven sequential helices that cross the transmembrane, allowing the receptor to correctly insert into the cell membrane and couple with the G protein. This coupling permits the receptor to modulate signaling cascades. &#x000a0;The dopamine receptor is a type of G-protein coupled receptor. Dopamine receptors can also act through G-protein independent mechanisms such as ion channel interactions.&#x000a0;</p>
        <p>Dopamine is a monoamine catecholamine neurotransmitter and hormone. It binds to the dopamine receptor and, depending on the type of receptor, has many different functions. Dopamine receptors are mostly present in the central nervous system.<xref ref-type="bibr" rid="article-20660.r2">[2]</xref></p>
      </sec>
      <sec id="article-20660.s3" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>The dopamine receptors are located and encoded by different genes. D1 receptor encoding is by the gene 5q31-q34. The D2 receptor is on chromosome 11, along with the D4 receptor, while the D3 receptor is located on the third chromosome. The D5 receptor is on the fourth chromosome.<xref ref-type="bibr" rid="article-20660.r2">[2]</xref><xref ref-type="bibr" rid="article-20660.r3">[3]</xref></p>
      </sec>
      <sec id="article-20660.s4" sec-type="Function">
        <title>Function</title>
        <p>Dopamine receptors play an essential role in daily life functions. This hormone and its receptors affect movement, emotions, and the reward system in the brain.</p>
        <p>Dopamine receptors are expressed in the central nervous system, specifically in the hippocampal dentate gyrus and subventricular zone. Dopamine receptors are also expressed in the periphery, more prominently in the kidney and vasculature,</p>
        <p>There are five types of dopamine receptors, which include D1, D2, D3, D4, and D5. Each receptor has a different function and is found in different locations.</p>
        <p>The function of each dopamine receptor<xref ref-type="bibr" rid="article-20660.r4">[4]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>D1: memory, attention, impulse control, regulation of renal function, locomotion</p>
          </list-item>
          <list-item>
            <p>D2: locomotion, attention, sleep, memory, learning</p>
          </list-item>
          <list-item>
            <p>D3: cognition, impulse control, attention, sleep</p>
          </list-item>
          <list-item>
            <p>D4: cognition, memory, fear, impulse control, attention, sleep</p>
          </list-item>
          <list-item>
            <p>D5: decision making, cognition, attention, renin secretion</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20660.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The five different dopamine receptors can subdivide into two categories. D1 and D5 receptors group together, and D2, D3, and D4 are together in a separate subgrouping.&#x000a0;</p>
        <p>D1 and D5 receptors couple to G stimulatory sites and activate adenylyl cyclase. The activation of adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. &#x000a0;</p>
        <p>D2 through D4 receptors couple to G inhibitory sites, which inhibit adenylyl cyclase and activate K+ channels.&#x000a0;</p>
        <p>The D1 receptor is the most abundant out of the five in the central nervous system, followed by D2, then D3, and D5, and the least abundant is D4. D1 receptors help regulate the development of neurons when the dopamine hormone binds to them.</p>
        <p>D1 and D5 receptors have high density in the striatum, nucleus accumbens, olfactory bulb, and substantia nigra. These receptors are essential in regulating the reward system, motor activity, memory, and learning. D1 and D5 receptors, along with stimulating adenyl cyclase, also activate phospholipase C, which leads to the induction of intracellular calcium release and activation of protein kinase C. Protein kinase C is a calcium-dependent protein kinase. Calcium is also involved in modulating neurotransmitter release by exocytosis. D1 and D5 receptors are also involved in the kidney by inhibiting Na/K ATPase through PKA and PKC pathways. In the kidney, these receptors correlate with an increase in electrolyte excretion and renal vasodilation.</p>
        <p>D2, D3, and D4 receptors are expressed mainly in the striatum, as well as the external globus pallidus, core of the nucleus accumbens, hippocampus, amygdala, and cerebral cortex. &#x000a0;These receptors also affect the postsynaptic receptor-medicated extrapyramidal activity. D2-D4 receptors are important in the signaling for the survival of human dopamine neurons and neuronal development.<xref ref-type="bibr" rid="article-20660.r4">[4]</xref><xref ref-type="bibr" rid="article-20660.r5">[5]</xref></p>
      </sec>
      <sec id="article-20660.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Many different diseases involve increased or decreased dopamine, leading to different effects. The two primary conditions discussed here, along with the pharmacology targeting dopamine receptors, are Parkinson disease and schizophrenia.</p>
        <p>Parkinson disease<xref ref-type="bibr" rid="article-20660.r6">[6]</xref><xref ref-type="bibr" rid="article-20660.r7">[7]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>A disease caused by a decreased amount of dopamine in the substantia nigra (in the nigrostriatal pathway)</p>
          </list-item>
          <list-item>
            <p>Symptoms include resting tremor, bradykinesia, shuffling gait, postural instability</p>
          </list-item>
          <list-item>
            <p>Treatment for Parkinson disease includes medications that target to increase dopamine availability
<list list-type="bullet"><list-item><p>Bromocriptine is a D2 receptor agonist; other dopamine agonists include pramipexole and ropinirole</p></list-item><list-item><p>Amantadine increases dopamine availability by increasing the release of dopamine and decreasing reuptake</p></list-item><list-item><p>Carbidopa and levodopa are commonly used together; in the CNS, levodopa is converted into dopamine to increase the amount of dopamine in the CNS, and carbidopa inhibits DOPA decarboxylase, which blocks the peripheral conversion of levodopa to dopamine - this decreases the peripheral side effects of dopamine</p></list-item><list-item><p>Other medications, such as selegiline and tolcapone, inhibit the breakdown of dopamine, which increases the availability at the synapse</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Schizophrenia<xref ref-type="bibr" rid="article-20660.r8">[8]</xref><xref ref-type="bibr" rid="article-20660.r9">[9]</xref><xref ref-type="bibr" rid="article-20660.r10">[10]</xref><xref ref-type="bibr" rid="article-20660.r9">[9]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Associated with an increase in dopaminergic activity</p>
          </list-item>
          <list-item>
            <p>Genetic and environmental risk factors affect the dopamine function</p>
          </list-item>
          <list-item>
            <p>Diagnosis includes greater than 6 months of at least 2 of the following: delusions, disorganized speech, hallucinations, disorganized behavior, and negative symptoms (anhedonia, flat affect, etc.), and at least one of the symptoms needs to be hallucinations, delusions, or disorganized speech</p>
          </list-item>
          <list-item>
            <p>Treatment for schizophrenia includes medications that target to decrease dopamine availability, which includes atypical and typical antipsychotics
<list list-type="bullet"><list-item><p>Typical antipsychotics are also known as first-generation antipsychotics - these drugs block the D2 receptor
<list list-type="bullet"><list-item><p>High potency typical antipsychotics include haloperidol, trifluoperazine, and fluphenazine</p></list-item><list-item><p>Low potency typical antipsychotics include chlorpromazine and thioridazine.</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Atypical antipsychotics have unique characteristics
<list list-type="bullet"><list-item><p>Most are D2 antagonists and also affect other receptors, such as the serotonin and histamine receptors; aripiprazole is D2 partial agonist</p></list-item><list-item><p>Atypical antipsychotics bind more loosely to the dopamine D2 receptor than the typical antipsychotics</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20660.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20660&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20660">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20660/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20660">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20660.s8">
        <title>References</title>
        <ref id="article-20660.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beaulieu</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Espinoza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gainetdinov</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Dopamine receptors - IUPHAR Review 13.</article-title>
            <source>Br J Pharmacol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>172</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-23</page-range>
            <pub-id pub-id-type="pmid">25671228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20660.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grandy</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Litt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bunzow</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Marchionni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Makam</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Magenis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Civelli</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP.</article-title>
            <source>Am J Hum Genet</source>
            <year>1989</year>
            <month>Nov</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>778</fpage>
            <page-range>778-85</page-range>
            <pub-id pub-id-type="pmid">2573278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20660.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grandy</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Magenis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Civelli</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Chromosomal localization of three human D5 dopamine receptor genes.</article-title>
            <source>Genomics</source>
            <year>1992</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>968</fpage>
            <page-range>968-73</page-range>
            <pub-id pub-id-type="pmid">1387108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20660.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mishra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shukla</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson's disease.</article-title>
            <source>J Exp Neurosci</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>1179069518779829</fpage>
            <pub-id pub-id-type="pmid">29899667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20660.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vekshina</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Anokhin</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Veretinskaya</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Shamakina</surname>
                <given-names>IY</given-names>
              </name>
            </person-group>
            <article-title>[Heterodimeric D1-D2 dopamine receptors: a review].</article-title>
            <source>Biomed Khim</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-12</page-range>
            <pub-id pub-id-type="pmid">28251946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20660.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ehgoetz Martens</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Georgiades</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Walton</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>SJG</given-names>
              </name>
              <name>
                <surname>Shine</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson's disease.</article-title>
            <source>Neuroimage</source>
            <year>2017</year>
            <month>May</month>
            <day>15</day>
            <volume>152</volume>
            <fpage>207</fpage>
            <page-range>207-220</page-range>
            <pub-id pub-id-type="pmid">28263926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20660.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>You</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Mangone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Le Febvre de Nailly</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Charbonnier-Beaupel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Corvol</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease.</article-title>
            <source>Cell Tissue Res</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>373</volume>
            <issue>1</issue>
            <fpage>111</fpage>
            <page-range>111-135</page-range>
            <pub-id pub-id-type="pmid">29516217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20660.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howes</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>McCutcheon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia.</article-title>
            <source>Biol Psychiatry</source>
            <year>2017</year>
            <month>Jan</month>
            <day>01</day>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-20</page-range>
            <pub-id pub-id-type="pmid">27720198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20660.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tardy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huhn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Leucht</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Aug</month>
            <day>03</day>
            <issue>8</issue>
            <fpage>CD009230</fpage>
            <pub-id pub-id-type="pmid">25087165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20660.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seeman</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>An update of fast-off dopamine D2 atypical antipsychotics.</article-title>
            <source>Am J Psychiatry</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>162</volume>
            <issue>10</issue>
            <fpage>1984</fpage>
            <page-range>1984-5</page-range>
            <pub-id pub-id-type="pmid">16199855</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
